CDXS Stock Overview
Codexis, Inc. discovers, develops, and sells enzymes and other proteins. More details
Snowflake Score | |
---|---|
Valuation | 1/6 |
Future Growth | 1/6 |
Past Performance | 0/6 |
Financial Health | 5/6 |
Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Codexis, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$4.93 |
52 Week High | US$6.08 |
52 Week Low | US$2.53 |
Beta | 2.16 |
1 Month Change | 6.94% |
3 Month Change | 70.59% |
1 Year Change | 58.01% |
3 Year Change | -85.53% |
5 Year Change | -69.36% |
Change since IPO | -62.82% |
Recent News & Updates
Is Codexis (NASDAQ:CDXS) Using Debt In A Risky Way?
Dec 10Codexis, Inc.'s (NASDAQ:CDXS) 29% Jump Shows Its Popularity With Investors
Nov 07Recent updates
Is Codexis (NASDAQ:CDXS) Using Debt In A Risky Way?
Dec 10Codexis, Inc.'s (NASDAQ:CDXS) 29% Jump Shows Its Popularity With Investors
Nov 07After Leaping 26% Codexis, Inc. (NASDAQ:CDXS) Shares Are Not Flying Under The Radar
Jul 26Is Codexis (NASDAQ:CDXS) Weighed On By Its Debt Load?
Jul 12Investors Appear Satisfied With Codexis, Inc.'s (NASDAQ:CDXS) Prospects
May 29Codexis, Inc.'s (NASDAQ:CDXS) Shares Leap 56% Yet They're Still Not Telling The Full Story
Dec 20What Does Codexis, Inc.'s (NASDAQ:CDXS) Share Price Indicate?
Dec 19Is Codexis (NASDAQ:CDXS) In A Good Position To Deliver On Growth Plans?
Nov 15Lacklustre Performance Is Driving Codexis, Inc.'s (NASDAQ:CDXS) Low P/S
Jun 28Calculating The Intrinsic Value Of Codexis, Inc. (NASDAQ:CDXS)
Jun 07At US$3.41, Is It Time To Put Codexis, Inc. (NASDAQ:CDXS) On Your Watch List?
May 09Analysts Just Made A Major Revision To Their Codexis, Inc. (NASDAQ:CDXS) Revenue Forecasts
Feb 27We're Not Worried About Codexis' (NASDAQ:CDXS) Cash Burn
Feb 25Is Codexis, Inc. (NASDAQ:CDXS) Trading At A 28% Discount?
Nov 05Codexis appoints Kevin Norrett as chief operating officer
Oct 03We Think Codexis (NASDAQ:CDXS) Can Afford To Drive Business Growth
Aug 23Analysts Have Just Cut Their Codexis, Inc. (NASDAQ:CDXS) Revenue Estimates By 10%
Jul 28Codexis: Profitability, Return On Capital Are Persistent Headwinds Looking Ahead
Jul 27Shareholder Returns
CDXS | US Life Sciences | US Market | |
---|---|---|---|
7D | -12.1% | -2.1% | -2.7% |
1Y | 58.0% | -5.5% | 23.4% |
Return vs Industry: CDXS exceeded the US Life Sciences industry which returned -5.5% over the past year.
Return vs Market: CDXS exceeded the US Market which returned 23.4% over the past year.
Price Volatility
CDXS volatility | |
---|---|
CDXS Average Weekly Movement | 9.8% |
Life Sciences Industry Average Movement | 9.1% |
Market Average Movement | 6.3% |
10% most volatile stocks in US Market | 16.9% |
10% least volatile stocks in US Market | 3.2% |
Stable Share Price: CDXS has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: CDXS's weekly volatility (10%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2002 | 174 | Stephen Dilly | www.codexis.com |
Codexis, Inc. discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services.
Codexis, Inc. Fundamentals Summary
CDXS fundamental statistics | |
---|---|
Market cap | US$429.68m |
Earnings (TTM) | -US$62.09m |
Revenue (TTM) | US$64.45m |
6.2x
P/S Ratio-6.5x
P/E RatioIs CDXS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
CDXS income statement (TTM) | |
---|---|
Revenue | US$64.45m |
Cost of Revenue | US$60.89m |
Gross Profit | US$3.55m |
Other Expenses | US$65.64m |
Earnings | -US$62.09m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -0.76 |
Gross Margin | 5.51% |
Net Profit Margin | -96.35% |
Debt/Equity Ratio | 39.0% |
How did CDXS perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2024/12/23 00:34 |
End of Day Share Price | 2024/12/23 00:00 |
Earnings | 2024/09/30 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Codexis, Inc. is covered by 20 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
J. Horwitz | Baird |
Vishal Shah | Barclays |
Robert Wasserman | Benchmark Company |